FDA's response wasn't what they expected: the agency had no established basis for believing that biomarker actually tracked with how patients felt or functioned day to day, and without that link, a clean p-value wasn't going to carry the program. The sponsor had generated rigorous evidence. It just wasn't evidence anyone downstream could act on. What followed was roughly 18 months retrofitting a patient-reported outcome measure into the confirmatory study a fix that would have cost a fraction of the time and money if someone had raised the question before the trial was designed around that endpoint in the first place.
-
2 Articles
-
1 Photos
-
0 Vidéos
-
Habitant USA
-
Du USA
-
Male
-
02/02/1991
-
Suivi par 0 membre
Rechercher
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian
